Insider Buying: TransMedics Group Inc (TMDX) Director Acquires 33,333 Shares of Stock

TransMedics Group Inc (NASDAQ:TMDX) Director Edwin M. Kania, Jr. bought 33,333 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The shares were bought at an average price of $16.00 per share, with a total value of $533,328.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Shares of TMDX traded up $0.84 during midday trading on Thursday, hitting $27.34. The stock had a trading volume of 263,600 shares, compared to its average volume of 282,179. TransMedics Group Inc has a 1 year low of $19.76 and a 1 year high of $31.54.

A number of brokerages recently weighed in on TMDX. Canaccord Genuity began coverage on shares of TransMedics Group in a research report on Tuesday. They set a “buy” rating and a $37.00 target price for the company. Cowen initiated coverage on shares of TransMedics Group in a research report on Tuesday. They set an “outperform” rating and a $40.00 target price for the company. JPMorgan Chase & Co. initiated coverage on shares of TransMedics Group in a research report on Tuesday. They set an “overweight” rating and a $34.00 price objective for the company. Finally, Morgan Stanley initiated coverage on shares of TransMedics Group in a research report on Tuesday. They set an “equal weight” rating for the company.

TRADEMARK VIOLATION WARNING: “Insider Buying: TransMedics Group Inc (TMDX) Director Acquires 33,333 Shares of Stock” was originally posted by Rockland Register and is owned by of Rockland Register. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://rocklandregister.com/2019/05/30/edwin-m-kania-jr-acquires-33333-shares-of-transmedics-group-inc-tmdx-stock.html.

About TransMedics Group

TransMedics, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation.

Featured Story: Average Daily Trade Volume – What You Need to Know

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.